229 related articles for article (PubMed ID: 33127414)
1. Reewarm™ PTX drug-coated balloon in the treatment of femoropopliteal artery disease: A multi-center, randomized controlled trial in China.
Ye W; Zhang X; Dai X; Huang X; Liu Z; Jiang M; Liu C
Int J Cardiol; 2021 Mar; 326():164-169. PubMed ID: 33127414
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
[TBL] [Abstract][Full Text] [Related]
3. Drug-Coated Balloon Angioplasty Versus Standard Uncoated Balloon Angioplasty for Long Femoropopliteal Lesions: Post Hoc Analysis of the 24-Month Results of the AcoArt I Study.
Jia S; Liu J; Sun G; Zhang J; Zhuang B; Jia X; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W;
Ann Vasc Surg; 2022 May; 82():70-80. PubMed ID: 34902474
[TBL] [Abstract][Full Text] [Related]
4. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
[TBL] [Abstract][Full Text] [Related]
5. Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of 200 Chinese Patients With Severe Femoropopliteal Lesions: 24-Month Results of AcoArt I.
Xu Y; Jia X; Zhang J; Zhuang B; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W
JACC Cardiovasc Interv; 2018 Dec; 11(23):2347-2353. PubMed ID: 30448170
[TBL] [Abstract][Full Text] [Related]
6. Three-Year Results of the IN.PACT SFA Japan Trial Comparing Drug-Coated Balloons With Percutaneous Transluminal Angioplasty.
Soga Y; Iida O; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H
J Endovasc Ther; 2020 Dec; 27(6):946-955. PubMed ID: 32865145
[TBL] [Abstract][Full Text] [Related]
7. Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA.
Laird JR; Schneider PA; Tepe G; Brodmann M; Zeller T; Metzger C; Krishnan P; Scheinert D; Micari A; Cohen DJ; Wang H; Hasenbank MS; Jaff MR;
J Am Coll Cardiol; 2015 Dec; 66(21):2329-2338. PubMed ID: 26476467
[TBL] [Abstract][Full Text] [Related]
8. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
[TBL] [Abstract][Full Text] [Related]
9. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial.
Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
J Endovasc Ther; 2018 Feb; 25(1):109-117. PubMed ID: 29264999
[TBL] [Abstract][Full Text] [Related]
10. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
[TBL] [Abstract][Full Text] [Related]
11. Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.
Krishnan P; Farhan S; Schneider P; Kamran H; Iida O; Brodmann M; Micari A; Sachar R; Urasawa K; Scheinert D; Ando K; Tarricone A; Doros G; Tepe G; Yokoi H; Laird J; Zeller T
J Am Coll Cardiol; 2022 Sep; 80(13):1241-1250. PubMed ID: 36137674
[TBL] [Abstract][Full Text] [Related]
12. Impact of Patient and Lesion Characteristics on Drug-Coated Balloon Angioplasty in the Femoropopliteal Artery: A Pooled Analysis of Four Randomized Controlled Multicenter Trials.
Albrecht T; Ukrow A; Werk M; Tepe G; Zeller T; Meyer DR; Kutschera M; Speck U; Waliszewski M
Cardiovasc Intervent Radiol; 2019 Apr; 42(4):495-504. PubMed ID: 30539236
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons Versus Standard Percutaneous Transluminal Angioplasty: Results From the IN.PACT SFA II Trial.
Salisbury AC; Li H; Vilain KR; Jaff MR; Schneider PA; Laird JR; Cohen DJ
JACC Cardiovasc Interv; 2016 Nov; 9(22):2343-2352. PubMed ID: 27884360
[TBL] [Abstract][Full Text] [Related]
14. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
[No Abstract] [Full Text] [Related]
16. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
Bausback Y; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
J Endovasc Ther; 2017 Aug; 24(4):459-467. PubMed ID: 28558502
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a novel paclitaxel-nano-coated balloon for femoropopliteal angioplasty: one-year results of the EffPac trial.
Teichgräber U; Lehmann T; Aschenbach R; Scheinert D; Zeller T; Brechtel K; Blessing E; Lichtenberg M; Sixt S; Brucks S; Beschorner U; Klumb CT; Thieme M;
EuroIntervention; 2020 Apr; 15(18):e1633-e1640. PubMed ID: 31687933
[TBL] [Abstract][Full Text] [Related]
18. Drug-Coated vs Uncoated Percutaneous Transluminal Angioplasty in Infrapopliteal Arteries: Six-Month Results of the Lutonix BTK Trial.
Mustapha JA; Brodmann M; Geraghty PJ; Saab F; Settlage RA; Jaff MR;
J Invasive Cardiol; 2019 Aug; 31(8):205-211. PubMed ID: 31368893
[TBL] [Abstract][Full Text] [Related]
19. Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease.
Bausback Y; Wittig T; Schmidt A; Zeller T; Bosiers M; Peeters P; Brucks S; Lottes AE; Scheinert D; Steiner S
J Am Coll Cardiol; 2019 Feb; 73(6):667-679. PubMed ID: 30765033
[TBL] [Abstract][Full Text] [Related]
20. 1-Year Results From the RANGER II SFA Randomized Trial of the Ranger Drug-Coated Balloon.
Sachar R; Soga Y; Ansari MM; Kozuki A; Lopez L; Brodmann M; Schroë H; Ramanath VS; Diaz-Cartelle J; Zeller T;
JACC Cardiovasc Interv; 2021 May; 14(10):1123-1133. PubMed ID: 34016410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
